Biomarkers in Alzheimer’s disease

Alzheimer’s disease (AD) is a progressive neurodegenerative disease. AD is the main cause of dementia worldwide and aging is the main risk factor for developing the illness. AD classical diagnostic criteria rely on clinical data. However, the development of a biological definition of AD using biomar...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Janeiro Manuel H., Ardanaz Carlos G., Sola-Sevilla Noemí, Dong Jinya, Cortés-Erice María, Solas Maite, Puerta Elena, Ramírez María J.
Formato:	article
Lenguaje:	EN ES
Publicado:	De Gruyter 2020
Materias:	alzheimer’s disease β-amyloid blood cerebrospinal fluid cognitive deficit mild cognitive impairment neuroimaging Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/d6b9b9b2d980447d95839b69089cbe11
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d6b9b9b2d980447d95839b69089cbe11
record_format	dspace
spelling	oai:doaj.org-article:d6b9b9b2d980447d95839b69089cbe112021-12-05T14:10:39ZBiomarkers in Alzheimer’s disease2628-491X10.1515/almed-2020-0090https://doaj.org/article/d6b9b9b2d980447d95839b69089cbe112020-11-01T00:00:00Zhttps://doi.org/10.1515/almed-2020-0090https://doaj.org/toc/2628-491XAlzheimer’s disease (AD) is a progressive neurodegenerative disease. AD is the main cause of dementia worldwide and aging is the main risk factor for developing the illness. AD classical diagnostic criteria rely on clinical data. However, the development of a biological definition of AD using biomarkers that reflect the underling neuropathology is needed.Janeiro Manuel H.Ardanaz Carlos G.Sola-Sevilla NoemíDong JinyaCortés-Erice MaríaSolas MaitePuerta ElenaRamírez María J.De Gruyterarticlealzheimer’s diseaseβ-amyloidbloodcerebrospinal fluidcognitive deficitmild cognitive impairmentneuroimagingMedical technologyR855-855.5ENESAdvances in Laboratory Medicine, Vol 2, Iss 1, Pp 27-37 (2020)
institution	DOAJ
collection	DOAJ
language	EN ES
topic	alzheimer’s disease β-amyloid blood cerebrospinal fluid cognitive deficit mild cognitive impairment neuroimaging Medical technology R855-855.5
spellingShingle	alzheimer’s disease β-amyloid blood cerebrospinal fluid cognitive deficit mild cognitive impairment neuroimaging Medical technology R855-855.5 Janeiro Manuel H. Ardanaz Carlos G. Sola-Sevilla Noemí Dong Jinya Cortés-Erice María Solas Maite Puerta Elena Ramírez María J. Biomarkers in Alzheimer’s disease
description	Alzheimer’s disease (AD) is a progressive neurodegenerative disease. AD is the main cause of dementia worldwide and aging is the main risk factor for developing the illness. AD classical diagnostic criteria rely on clinical data. However, the development of a biological definition of AD using biomarkers that reflect the underling neuropathology is needed.
format	article
author	Janeiro Manuel H. Ardanaz Carlos G. Sola-Sevilla Noemí Dong Jinya Cortés-Erice María Solas Maite Puerta Elena Ramírez María J.
author_facet	Janeiro Manuel H. Ardanaz Carlos G. Sola-Sevilla Noemí Dong Jinya Cortés-Erice María Solas Maite Puerta Elena Ramírez María J.
author_sort	Janeiro Manuel H.
title	Biomarkers in Alzheimer’s disease
title_short	Biomarkers in Alzheimer’s disease
title_full	Biomarkers in Alzheimer’s disease
title_fullStr	Biomarkers in Alzheimer’s disease
title_full_unstemmed	Biomarkers in Alzheimer’s disease
title_sort	biomarkers in alzheimer’s disease
publisher	De Gruyter
publishDate	2020
url	https://doaj.org/article/d6b9b9b2d980447d95839b69089cbe11
work_keys_str_mv	AT janeiromanuelh biomarkersinalzheimersdisease AT ardanazcarlosg biomarkersinalzheimersdisease AT solasevillanoemi biomarkersinalzheimersdisease AT dongjinya biomarkersinalzheimersdisease AT cortesericemaria biomarkersinalzheimersdisease AT solasmaite biomarkersinalzheimersdisease AT puertaelena biomarkersinalzheimersdisease AT ramirezmariaj biomarkersinalzheimersdisease
_version_	1718371868631629824

Biomarkers in Alzheimer’s disease

Ejemplares similares